SCLX FINANCIAL STATEMENTS

Scilex Holding Company — balance sheet, income statement and cash flow trends

SCLXScilex Holding Company

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - General

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue33.9 M $-33.2%

Gross Profit20.2 M $-44.6%

Operating Income-276.7 M $—

EBITDA-333.3 M $—

Net Income-419.7 M $—

Peer Comparison· Drug Manufacturers - General

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
SCLX	-33.2%	59.7%	-984.4%	-1,239.4%
ANGEN	11.7%	58.8%	9.8%	-45.0%
HIK	7.4%	41.4%	20.0%	12.0%
LKMNH	19.8%	18.8%	26.4%	3.2%
MEDTR	6.5%	30.9%	9.4%	0.2%
RTALB	24.0%	35.1%	9.0%	136.3%
Industry median	3.3%	70.7%	28.4%	15.0%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
SCLX	-33.2%	59.7%	-984.4%	-1,239.4%
DCGO	-42.0%	29.5%	-51.8%	-62.2%
LUNG	1.2%	75.5%	-54.5%	-60.1%
PDSB	-100.0%	—	—	—
PMVP	—	—	—	—
VRCA	417.6%	89.5%	-30.6%	-48.0%
Industry median	3.3%	70.7%	28.4%	15.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Current Liabilities501.8 M $92%
Long-term Liabilities46 M $8%

Key Figures

YoY change

Total Assets293.6 M $+271.8%

Total Liabilities547.7 M $+88.6%

Total Equity-249.2 M $—

Cash & ST Investments3.4 M $-42.1%

Total Debt106.4 M $+156.2%

Net Debt103 M $+188.5%

Peer Comparison· Drug Manufacturers - General

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
SCLX	0.08	-42.7%	-0.31	-84.9%
ANGEN	2.31	28.1%	4.71	67.2%
HIK	1.82	61.8%	1.87	45.7%
LKMNH	0.83	99.0%	1.96	41.6%
MEDTR	3.58	1.0%	-1.64	83.0%
RTALB	1.21	1.2%	0.90	84.9%
Industry median	1.25	94.3%	1.35	28.4%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
SCLX	0.08	-42.7%	-0.31	-84.9%
DCGO	1.79	21.5%	0.05	63.2%
LUNG	4.91	123.0%	0.11	38.1%
PDSB	2.26	407.5%	0.21	15.8%
PMVP	11.14	0.3%	1.19	91.1%
VRCA	2.02	9.0%	1.69	41.4%
Industry median	1.25	94.3%	1.35	28.4%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-3.3 M $-120.7%

Capital Expenditures3.4 M $+472.2%

Free Cash Flow-6.1 M $-139.9%

Dividends Paid525 K $—

Peer Comparison· Drug Manufacturers - General

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
SCLX	-9.7%	-18.1%	10.1%	0.8%
ANGEN	40.2%	-21.2%	61.5%	-89.3%
HIK	11.6%	5.8%	5.8%	96.8%
LKMNH	8.4%	-9.7%	18.2%	264.8%
MEDTR	21.1%	27.9%	6.6%	10,700.8%
RTALB	58.5%	88.6%	10.8%	42.9%
Industry median	23.7%	18.5%	5.3%	137.9%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
SCLX	-9.7%	-18.1%	10.1%	0.8%
DCGO	-1,543,776.9%	-1,686,400.7%	142,623.8%	2,480,744.4%
LUNG	-33.1%	-33.3%	0.2%	55.1%
PDSB	—	—	—	13,162.3%
PMVP	—	—	—	95.7%
VRCA	-38.0%	-38.0%	0.0%	79.2%
Industry median	23.7%	18.5%	5.3%	137.9%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on SCLX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 6, 26. This content is for informational purposes only and is not investment advice.